Ravi Bhatt

Ravi Bhatt has led the clinical development of MAGE-A4 TCR-engineered T cell therapy, which achieved the first FDA approval of a TCR-based cell therapy for synovial sarcoma. His work has characterized MAGE-A4 expression across tumor types and established biomarker strategies for patient selection. He has advanced high-affinity TCR engineering techniques that improve tumor recognition while maintaining safety. His research has established TCR therapy as a validated modality for antigen-specific solid tumor treatment.